Innovent Forms Three-Drug $391.5 Million Collaboration with Incyte

Suzhou Innovent formed a $391.5 million collaboration for China rights to three clinical-stage drug candidates developed by Incyte of Palo Alto, CA. Innovent will make a $40 upfront payment, then follow with a $20 million milestone payment when it files its first China IND. It will also be responsible for $331.5 million in development, regulatory and commercial milestones. For Innovent, the agreement is the first time the company has ventured outside of its primary focus on antibody candidates. It expects to file the first IND in 2019. More details.... Stock Symbols: (HK: 01801) (NSDQ: INCY) Share this with colleagues: // //